A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy

A Multi-Center, Longitudinal, Prospective, Observational, Multi-Cohort Study of Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment (LIST, Lung Initiative on Sequence Therapy)

The purpose of this trial is to describe the following, for each cohort, in real world conditions in France:

• The characteristics and treatment sequence of patients treated with nivolumab
• The effectiveness of nivolumab treatment
• The safety profile of nivolumab
• Treatment patterns (e.g. duration of treatment, subsequent treatments) of nivolumab
• The patient-reported outcomes (PRO) in patients treated with nivolumab, at baseline and during follow up using the EuroQoL-5D-3L

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Pathologically confirmed diagnosis of advanced NSCLC
• Whose physician has already decided to initiate a treatment with nivolumab for the treatment of advanced NSCLC according to the European label
• Previously treated with at least one prior chemotherapy- containing regimen

Exclusion Criteria:

• Participants taking part in an interventional study for lung cancer treatment for which nivolumab is one of the investigational drugs
• Participants with a diagnosis of another primary cancer within the past five years
• Participants receiving IO within 12 weeks prior to nivolumab first infusion in the context of the present study

Other protocol-defined inclusion/exclusion criteria apply